Unfortunately, war is the daily media lead. We get the numbers of dead and injured for each conflict. You might consider those just injured as ‘lucky’ if you’re like me. Au contraire. Familiar issues are traumatic brain and spine injuries. Alongside lost limbs and wounds caused by bomb debris and emotional symptoms such as PTSD and depression that may persist for years, sometimes a lifetime. (Xaigham.com)
For life-saving technologies, war has unfortunately become a growth sector. I take no pleasure in saying that.
A sudden, traumatic blow to the spine (tSCI) can fracture, dislocate, crush or compress one or more of the vertebrae. A gunshot or knife wound that penetrates and cuts the spinal cord also can cause a spinal cord injury. Additional damage usually occurs over days or weeks.
The global Spinal Cord Trauma Treatment market was valued at US$ 2458.9 million in 2022 and is projected to reach US$ 3009.4 million by 2029, at a CAGR of 2.9% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The current Middle East conflict was not included. Unfortunately, those projected growth numbers could rise significantly.
While I am using the wars and conflicts as examples of the growth of the traumatic injury market, it was already significant and this is just the US.
The question arises: how is this issue addressed? There are myriad companies, large and small, looking for answers.
TORONTO and HAIFA, Israel, Jan. 05, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries.
How does it work? Stay with me; it’s pretty straightforward.
Part One: Active Ingredients
Exosomes: Exosomes, also known as extracellular vesicles, are nano-sized, naturally occurring particles in the body, secreted by cells. Exosomes, also known as extracellular vesicles, are nano-sized, naturally occurring particles in the body, secreted by cells. Can be administered non-invasively, intranasally
Part Two: Delivery
ExoTherapy: Exosomes, loaded with therapeutic molecules, cross the blood-brain barrier and reach cells and tissues for regeneration, rewiring and recovery.
Part Three: Effect
SiRNA-PTEN: The suggested PTEN inhibition-based therapeutic targets are nerve growth and regeneration after injury or damage, treatment of cardiac ischemia/reperfusion and associated disease, wound repair, and infertility.
The goal is to reverse this traumatic brain trauma as well as develop other health issues such as depression—no small accomplishment. The US FDA has granted NRX Orphan Drug Status.
The Orphan Drug Designation program provides orphan status to drugs and biologics for rare diseases that meet specific criteria. Orphan drug designation provides incentives, including:
“Orphan-drug designation is expected to streamline our go-to-market, shorten our regulatory process, save the Company millions of dollars, and provide valuable market exclusivity. We appreciate the formal recognition of the potential impact of our therapy on the lives of patients suffering from acute spinal cord injuries,” said Dr. Shaltiel, CEO of NurExone Biologic, Ltd.
The Company also holds an exclusive worldwide license from Technion and Tel Aviv University for developing and commercializing the technology.
This technology is not only promising but appears well destined for success. In their totality, the current NRX out-front therapies could bring much relief to those seriously ‘injured’ patients who live with chronic pain and myriad challenges daily.
NurExome is a cutting-edge medical technology company. While trading has been modest, it paints a positive investment picture for the previously reasons stated. Will it pop tomorrow? No. That I can guarantee.
A savvy plan would to be to approach as a dollar-cost average investment. The deeper you dig, the more potential will become apparent.
Note Hyperlinks below.
Stock stats Jan 5 2024 | |
52 Week Range | 0.1000 0.4200 |
Volume | 7,000 |
Avg. Volume | 4,511 |
Market Cap | 14.475M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.1100 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 4.01 |
In-depth Corporate Presentation Litchfield Research |
October 17, 2022
Marc ZERBOLA CHALLANDE
Pharmagreen Biotech (OTC: PHBI), a company providing the highest quality starter plantlets cannabis/hemp plants and any plant species on this planet utilizing a proprietary tissue culture process, “Chibafreen,” to licensed cannabis cultivators and CBD / CBG hemp farmers, recently welcomed Ethan Styles to its board. Strong from his past rich experience, Mr. Styles will aim to lead Pharmagreen’s development of health and wellness formulations for everyone around the world.
Pharmagreen Biotech is a company located in California where it builds its farm. We could define the company as innovative because it utilizes the revolutionary Internet of Things (IoT) to reduce the disease and contamination of plants. In other words, Pharmagreen builds state-of-the-art facilities that use the latest environmental, fertigation, and sanitation control technologies. This technique ensures that every batch of new plantlets from the mother plant thrives and, as a positive consequence, reduces costs and solidifies the supply chain. The Long Valley Farms is where the company is mainly focused, and Pharmagreen currently completes fundraising for the acquisition. Pharmagreen targets immediate and significant revenue thanks to the micro-business license application processed by Mendocino County, California, and various relevant governing bodies. According to Peter Wojcik (CEO), the company is laser-focused on getting revenues with the lowest CAPEX as soon as possible. Once the licenses get approved, Mr. Wojcik explains they will add cannabis-based products, both stand-alone and combined with other ingredients, to target specific ailments and help people prevent illness first. In early September, the company announced it had developed its first formulated nutraceutical product.
Ethan Styles joined the company as Vice President of Product Research and Development. Mr. Styles has substantial industry experience because he has worked with medicinal plants, cannabis, medicinal plants, and fungi. Combined with years of personal studies in molecular biology, Ethan has keen insight into the human health benefits these plants provide. Connected to Peter Wojcik’s and the company’s experience, Pharmagreen will be able to use this knowledge of vegans, organics, tissue culture (Chibafreen), good farming practices, molecular biology and genomic technologies in the future production of plant and fungi biomaterial.
“My aim as V. P. of Research and Development is to simplify health and wellness and give humanity the ability to experience the best out of life. Through ancient knowledge and today’s most advanced technologies, we can develop a way of life unknown to most of the population,” Mr. Styles stated. “By using multiple genomic data platforms to cross reference client-specific data against historical and current genomic patterns, we have the ability to make straightforward recommendations regarding appropriate active ingredients. I look forward to leading Pharmagreen’s development of health and wellness formulations for everyone around the world.”
Ethan Styles
“It gives me great pleasure to have Mr. Styles join our corporate team. While getting to know Ethan for the last year and a half, I experienced his extensive knowledge of therapeutic plants and fungi firsthand. I learned from him what really matters when it comes to personalized health and wellness. He has been the missing link we were looking for in the production of nutraceutical whole plant and fungi-based human support product development, utilizing molecular biology and genomic-based sciences.”
Peter Wojcik
About nutraceuticals, the market was worth around USD $449.5 Billion in 2021 and is estimated to grow to about USD $745.5 billion by 2028. As per the analysis shared by Zion market research report, the Nutraceutical Market is expected to grow annually at a CAGR of around 8% (2022-2028).
The demand for functional foods will increase considerably through 2030 owing to several health benefits, including weight management and improved blood circulation. These products also aid individuals with cardiovascular and obesity issues, which will drive the growth of the functional foods segment. Regarding distribution channels, E-commerce represented a strong segment as it generated USD $116.3B in revenue in 2021. Rising demand for a faster and easier shopping experience will further push the industry size from the E-commerce distribution channel. North America holds the most significant market share worldwide by gathering 38.5%. The region should keep the most important market share thanks to the growth of key players in developing novel products. The covid pandemic has positively affected the overall development of the industry. Preventative measures against the virus buoyed the consumption of nutritious and functional foods with high zinc, sodium, vitamin D, vitamin C, and mineral content, escalating the sales of nutraceutical products.
The company’s stock price is worth $0.0098. If it recovers from its 52-week low of $0.004, the stock price will remain steady, hovering around $0.01. Besides, it could deserve to reach back its 52-week high of $0.03. What could significantly drive the market cap up is when Pharmagreen has its farms fully operational. The increase in revenue will help to boost the share price.
Pharmagreen Biotech (OTC: PHBI) remains significantly undervalued. If the company follows its strategy, it could lead the company to grab a significant market share. Adding Ethan Styles to the board marks a significant milestone and strengthens the company’s knowledge. The current share price doesn’t demonstrate the whole company’s potential, leading us to say it is an excellent opportunity to invest now and have a great return on investment in the near future.
Marc has been involved in the Stock Market Media Industry for the last +4 years. After obtaining a college degree in engineering in France, he moved to Canada, where he created Money,eh?, a personal finance website. He then contributed to building Guerilla Capital, a Capital Markets company and FirstPhase Media where he was head of research. At10xAlerts, he writes articles and conducts interviews on many sectors, including technology, metals & mining markets.
©2024 10xAlerts